Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2A1 | Q16548 | 7/20 | 0.39 |
| ▸ | BID | P55957 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 4/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12059332 | 0.87 | BCL2A1 (0.38) | BCL2A1CTSDBCHEACHEKCNH2 | |
| SCHEMBL6923285 | 0.86 | GRM5 (0.38) | ALDH1A1GFER | |
| SCHEMBL12059103 | 0.85 | L3MBTL1 (0.41) | BCL2A1BIDCTSDBCHEACHE | |
| SCHEMBL6920304 | 0.81 | RAB9A (0.39) | ALDH1A1BCHEACHE | |
| SCHEMBL6922000 | 0.79 | ACHE (0.38) | CTSDBCHEACHEKCNH2GRM2 | |
| SCHEMBL6922592 | 0.74 | CYP2D6 (0.40) | ALDH1A1CTSDBCHEACHEGRM2 | |
| SCHEMBL6923330 | 0.74 | KDM4E (0.58) | ALDH1A1BCHEACHE | |
| SCHEMBL6921722 | 0.73 | GRM5 (0.41) | — | |
| SCHEMBL6921643 | 0.73 | MEN1 (0.57) | ALDH1A1BCHEACHE | |
| SCHEMBL6923595 | 0.73 | GRM2 (0.41) | BCL2A1BIDALDH1A1GFERGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | BCL2A1 3768/4885BID 2219/4885ALDH1A1 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.